{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,6,17]],"date-time":"2026-06-17T01:13:28Z","timestamp":1781658808692,"version":"3.54.5"},"reference-count":57,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2020,2,18]],"date-time":"2020-02-18T00:00:00Z","timestamp":1581984000000},"content-version":"tdm","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by\/4.0\/"},{"start":{"date-parts":[[2020,2,18]],"date-time":"2020-02-18T00:00:00Z","timestamp":1581984000000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"funder":[{"name":"Otsuka Pharmaceutical Development & Commercialization, Inc.","award":["NA"],"award-info":[{"award-number":["NA"]}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["BMC Health Serv Res"],"published-print":{"date-parts":[[2020,12]]},"abstract":"<jats:title>Abstract<\/jats:title>\n                  <jats:sec>\n                    <jats:title>Background<\/jats:title>\n                    <jats:p>Autosomal dominant polycystic kidney disease (ADPKD) is one of the most common inherited kidney diseases characterized by progressive development of renal cysts and numerous extra-renal manifestations, eventually leading to kidney failure. Given its chronic and progressive nature, ADPKD is expected to carry a substantial economic burden over the course of the disease. However, there is a paucity of evidence on the impact of ADPKD from a societal perspective. This study aimed to estimate the direct and indirect costs associated with ADPKD in the United States (US).<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Methods<\/jats:title>\n                    <jats:p>A prevalence-based approach using data from scientific literature, and governmental and non-governmental organizations was employed to estimate direct healthcare costs (i.e., medical services, prescription drugs), direct non-healthcare costs (i.e., research and advocacy, donors\/recipients matching for kidney transplants, transportation to\/from dialysis centers), and indirect costs (i.e., patient productivity loss from unemployment, reduced work productivity, and premature mortality, caregivers\u2019 productivity loss and healthcare costs). The incremental costs associated with ADPKD were calculated as the difference between costs incurred over a one-year period by individuals with ADPKD and the US population. Sensitivity analyses using different sources and assumptions were performed to assess robustness of estimates and account for variability in published estimates.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Results<\/jats:title>\n                    <jats:p>The estimated total annual costs attributed to ADPKD in 2018 ranged from $7.3 to $9.6 billion in sensitivity analyses, equivalent to $51,970 to $68,091 per individual with ADPKD. In the base scenario, direct healthcare costs accounted for $5.7 billion (78.6%) of the total $7.3 billion costs, mostly driven by patients requiring renal replacement therapy ($3.2 billion; 43.3%). Indirect costs accounted for $1.4 billion (19.7%), mostly driven by productivity loss due to unemployment ($784 million; 10.7%) and reduced productivity at work ($390 million; 5.3%). Total excess direct non-healthcare costs were estimated at $125 million (1.7%).<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Conclusions<\/jats:title>\n                    <jats:p>ADPKD carries a considerable economic burden, predominantly attributed to direct healthcare costs, the majority of which are incurred by public and private healthcare payers. Effective and timely interventions to slow down the progression of ADPKD could substantially reduce the economic burden of ADPKD.<\/jats:p>\n                  <\/jats:sec>","DOI":"10.1186\/s12913-020-4974-4","type":"journal-article","created":{"date-parts":[[2020,2,18]],"date-time":"2020-02-18T13:03:01Z","timestamp":1582030981000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":38,"title":["The societal economic burden of autosomal dominant polycystic kidney disease in the United States"],"prefix":"10.1186","volume":"20","author":[{"given":"Martin","family":"Cloutier","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ameur M.","family":"Manceur","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Annie","family":"Guerin","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Myrlene Sanon","family":"Aigbogun","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Dorothee","family":"Oberdhan","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-9439-595X","authenticated-orcid":false,"given":"Marjolaine","family":"Gauthier-Loiselle","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2020,2,18]]},"reference":[{"issue":"9569","key":"4974_CR1","doi-asserted-by":"publisher","first-page":"1287","DOI":"10.1016\/S0140-6736(07)60601-1","volume":"369","author":"VE Torres","year":"2007","unstructured":"Torres VE, Harris PC, Pirson Y. Autosomal dominant polycystic kidney disease. Lancet. 2007;369(9569):1287\u2013301.","journal-title":"Lancet"},{"issue":"4","key":"4974_CR2","doi-asserted-by":"publisher","first-page":"362","DOI":"10.1159\/000343281","volume":"36","author":"I Helal","year":"2012","unstructured":"Helal I, et al. Prevalence of cardiovascular events in patients with autosomal dominant polycystic kidney disease. Am J Nephrol. 2012;36(4):362\u201370.","journal-title":"Am J Nephrol"},{"issue":"10","key":"4974_CR3","doi-asserted-by":"publisher","first-page":"556","DOI":"10.1038\/nrneph.2011.109","volume":"7","author":"JJ Grantham","year":"2011","unstructured":"Grantham JJ, Mulamalla S, Swenson-Fields KI. Why kidneys fail in autosomal dominant polycystic kidney disease. Nat Rev Nephrol. 2011;7(10):556\u201366.","journal-title":"Nat Rev Nephrol"},{"issue":"14","key":"4974_CR4","doi-asserted-by":"publisher","first-page":"1477","DOI":"10.1056\/NEJMcp0804458","volume":"359","author":"JJ Grantham","year":"2008","unstructured":"Grantham JJ. Clinical practice. Autosomal dominant polycystic kidney disease. N Engl J Med. 2008;359(14):1477\u201385.","journal-title":"N Engl J Med"},{"key":"4974_CR5","volume-title":"Fact Sheet: Autosomal Dominant Polycystic Kidney Disease","author":"National Institutes of Health","year":"2010","unstructured":"National Institutes of Health. Fact Sheet: Autosomal Dominant Polycystic Kidney Disease. 2010; 'https:\/\/report.nih.gov\/NIHfactsheets\/Pdfs\/AutosomalDominantPolycysticKidneyDisease(NIDDK).pdf Accessed 30 May 2019]."},{"key":"4974_CR6","doi-asserted-by":"publisher","first-page":"53","DOI":"10.2147\/IJNRD.S136359","volume":"11","author":"RA Barnawi","year":"2018","unstructured":"Barnawi RA, et al. Is the light at the end of the tunnel nigh? A review of ADPKD focusing on the burden of disease and tolvaptan as a new treatment. Int J Nephrol Renovasc Dis. 2018;11:53\u201367.","journal-title":"Int J Nephrol Renovasc Dis"},{"issue":"4","key":"4974_CR7","doi-asserted-by":"publisher","first-page":"303","DOI":"10.3111\/13696998.2014.985381","volume":"18","author":"CM Blanchette","year":"2015","unstructured":"Blanchette CM, et al. Hospital-based inpatient resource utilization associated with autosomal dominant polycystic kidney disease in the US. J Med Econ. 2015;18(4):303\u201311.","journal-title":"J Med Econ"},{"key":"4974_CR8","doi-asserted-by":"publisher","first-page":"65","DOI":"10.2147\/CEOR.S76269","volume":"7","author":"SM Brunelli","year":"2015","unstructured":"Brunelli SM, et al. End-stage renal disease in autosomal dominant polycystic kidney disease: a comparison of dialysis-related utilization and costs with other chronic kidney diseases. Clinicoecon Outcomes Res. 2015;7:65\u201372.","journal-title":"Clinicoecon Outcomes Res"},{"issue":"1","key":"4974_CR9","doi-asserted-by":"publisher","first-page":"560","DOI":"10.1186\/s12913-017-2513-8","volume":"17","author":"D Eriksson","year":"2017","unstructured":"Eriksson D, et al. Real-world costs of autosomal dominant polycystic kidney disease in the Nordics. BMC Health Serv Res. 2017;17(1):560.","journal-title":"BMC Health Serv Res"},{"key":"4974_CR10","doi-asserted-by":"publisher","first-page":"123","DOI":"10.2147\/CEOR.S75523","volume":"7","author":"T Knight","year":"2015","unstructured":"Knight T, et al. Medical resource utilization and costs associated with autosomal dominant polycystic kidney disease in the USA: a retrospective matched cohort analysis of private insurer data. Clinicoecon Outcomes Res. 2015;7:123\u201332.","journal-title":"Clinicoecon Outcomes Res"},{"issue":"8","key":"4974_CR11","doi-asserted-by":"publisher","first-page":"1471","DOI":"10.2215\/CJN.00780110","volume":"5","author":"KL Lentine","year":"2010","unstructured":"Lentine KL, et al. Renal function and healthcare costs in patients with polycystic kidney disease. Clin J Am Soc Nephrol. 2010;5(8):1471\u20139.","journal-title":"Clin J Am Soc Nephrol"},{"issue":"2","key":"4974_CR12","doi-asserted-by":"crossref","first-page":"134","DOI":"10.36469\/9861","volume":"1","author":"M Stephens","year":"2013","unstructured":"Stephens M, et al. High costs of Dialysis transportation in the United States: exploring approaches to a more cost-effective delivery system. JHEOR. 2013;1(2):134\u201350.","journal-title":"JHEOR"},{"issue":"7","key":"4974_CR13","doi-asserted-by":"publisher","first-page":"847","DOI":"10.1007\/s10198-016-0830-1","volume":"18","author":"G Turchetti","year":"2017","unstructured":"Turchetti G, et al. The social cost of chronic kidney disease in Italy. Eur J Health Econ. 2017;18(7):847\u201358.","journal-title":"Eur J Health Econ"},{"key":"4974_CR14","volume-title":"The descriptive epidemiology of autosomal dominant polycystic kidney disease (ADPKD) in the United States, 2013\u20132015","author":"CJ Willey","year":"2018","unstructured":"Willey, C.J., et al., The descriptive epidemiology of autosomal dominant polycystic kidney disease (ADPKD) in the United States, 2013\u20132015. Unpublished document, 2018."},{"key":"4974_CR15","volume-title":"Population Estimate Program","author":"US Census Bureau","year":"2018","unstructured":"US Census Bureau. Population Estimate Program. 2018 Available from: https:\/\/www.census.gov\/programs-surveys\/popest.html [10 July 2018]."},{"key":"4974_CR16","volume-title":"USRDS annual data report: Epidemiology of kidney disease in the United States","author":"United States Renal Data System","year":"2017","unstructured":"United States Renal Data System. USRDS annual data report: Epidemiology of kidney disease in the United States. Bethesda, MD: National Institutes of Health, National Institute of Diabetes and Digestive and Kidney Diseases; 2017."},{"issue":"6","key":"4974_CR17","doi-asserted-by":"publisher","first-page":"1472","DOI":"10.1093\/ndt\/gfs551","volume":"28","author":"HP Neumann","year":"2013","unstructured":"Neumann HP, et al. Epidemiology of autosomal-dominant polycystic kidney disease: an in-depth clinical study for South-Western Germany. Nephrol Dial Transplant. 2013;28(6):1472\u201387.","journal-title":"Nephrol Dial Transplant"},{"key":"4974_CR18","doi-asserted-by":"publisher","first-page":"45","DOI":"10.1016\/j.jad.2017.09.011","volume":"226","author":"M Cloutier","year":"2018","unstructured":"Cloutier M, et al. The economic burden of bipolar I disorder in the United States in 2015. J Affect Disord. 2018;226:45\u201351.","journal-title":"J Affect Disord"},{"key":"4974_CR19","first-page":"405","volume":"54","author":"PE Greenberg","year":"1993","unstructured":"Greenberg PE, Stiglin LE, Finkelstein SN. The economic burden of depression in 1990. J Clin Psychiatry. 1993;54:405\u201318.","journal-title":"J Clin Psychiatry"},{"issue":"6","key":"4974_CR20","doi-asserted-by":"publisher","first-page":"387","DOI":"10.1016\/0163-8343(86)90018-6","volume":"8","author":"A Stoudemire","year":"1986","unstructured":"Stoudemire A, et al. The economic burden of depression. Gen Hosp Psychiatry. 1986;8(6):387\u201394.","journal-title":"Gen Hosp Psychiatry"},{"issue":"5","key":"4974_CR21","doi-asserted-by":"publisher","first-page":"917","DOI":"10.2337\/dci18-0007","volume":"41","author":"American Diabetes Association","year":"2018","unstructured":"American Diabetes Association. Economic Costs of Diabetes in the U.S. in 2017. Diabetes Care. 2018;41(5):917\u201328.","journal-title":"Diabetes Care"},{"issue":"4","key":"4974_CR22","doi-asserted-by":"publisher","first-page":"1033","DOI":"10.2337\/dc12-2625","volume":"36","author":"American Diabetes, A","year":"2013","unstructured":"American Diabetes, A. Economic costs of diabetes in the U.S. in 2012. Diabetes Care. 2013;36(4):1033\u201346.","journal-title":"Diabetes Care"},{"issue":"12","key":"4974_CR23","doi-asserted-by":"publisher","first-page":"2017","DOI":"10.1185\/030079905X75087","volume":"21","author":"R Goeree","year":"2005","unstructured":"Goeree R, et al. The economic burden of schizophrenia in Canada in 2004. Curr Med Res Opin. 2005;21(12):2017\u201328.","journal-title":"Curr Med Res Opin"},{"issue":"5","key":"4974_CR24","doi-asserted-by":"publisher","first-page":"464","DOI":"10.1177\/070674379904400506","volume":"44","author":"R Goeree","year":"1999","unstructured":"Goeree R, et al. The economic burden of schizophrenia in Canada. Can J Psychiatr. 1999;44(5):464\u201372.","journal-title":"Can J Psychiatr"},{"issue":"9","key":"4974_CR25","doi-asserted-by":"publisher","first-page":"1122","DOI":"10.4088\/JCP.v66n0906","volume":"66","author":"EQ Wu","year":"2005","unstructured":"Wu EQ, et al. The economic burden of schizophrenia in the United States in 2002. J Clin Psychiatry. 2005;66(9):1122\u20139.","journal-title":"J Clin Psychiatry"},{"issue":"6","key":"4974_CR26","doi-asserted-by":"publisher","first-page":"764","DOI":"10.4088\/JCP.15m10278","volume":"77","author":"M Cloutier","year":"2016","unstructured":"Cloutier M, et al. The economic burden of schizophrenia in the United States in 2013. J Clin Psychiatry. 2016;77(6):764\u201371.","journal-title":"J Clin Psychiatry"},{"key":"4974_CR27","volume-title":"Consumer Price Index","author":"US Department of Labor Bureau of Labor Statistics","year":"2018","unstructured":"US Department of Labor Bureau of Labor Statistics. Consumer Price Index. 2018 Available from: https:\/\/www.bls.gov\/cpi\/home.htm; [13 June 2018]."},{"key":"4974_CR28","unstructured":"Cubanski J, et al. How much is enough? Out-of-pocket spending among Medicare beneficiaries: a chartbook. 2014: The Henry J. Kaiser Family Foundation. Washington, DC. Publication # 8612."},{"key":"4974_CR29","volume-title":"Medical Expenditure Panel Survey","author":"Center for Financing, Access, and Cost Trends, Agency for Healthcare Research and Quality","year":"2015","unstructured":"Center for Financing, Access, and Cost Trends, Agency for Healthcare Research and Quality. Medical Expenditure Panel Survey. 2015 Available from: https:\/\/meps.ahrq.gov\/mepstrends\/home\/index.html; [1 July 2018]."},{"issue":"1","key":"4974_CR30","doi-asserted-by":"publisher","first-page":"3","DOI":"10.1186\/s12882-016-0432-2","volume":"18","author":"C Small","year":"2017","unstructured":"Small C, et al. Non-dialysis dependent chronic kidney disease is associated with high total and out-of-pocket healthcare expenditures. BMC Nephrol. 2017;18(1):3.","journal-title":"BMC Nephrol"},{"key":"4974_CR31","volume-title":"PKD Foundation Annual Report 2017","author":"PKD Foundation","year":"2017","unstructured":"PKD Foundation. PKD Foundation Annual Report 2017. 2017 Available from: https:\/\/pkdcure.org\/wp-content\/uploads\/pkd_foundation_annual_report_2017.pdf; [1 July 2018]."},{"key":"4974_CR32","volume-title":"Estimates of Funding for Various Research, Condition, and Disease Categories (RCDC)","author":"National Institute of Health Research Portfolio Online Reporting Tools (RePORT)","year":"2018","unstructured":"National Institute of Health Research Portfolio Online Reporting Tools (RePORT). Estimates of Funding for Various Research, Condition, and Disease Categories (RCDC). 2018 Available from: https:\/\/report.nih.gov\/categorical_spending.aspx; [28 June 2018]."},{"key":"4974_CR33","volume-title":"OPTN\/UNOS Registration Fee Increase First Time Since 2013","author":"US Department of Health & Human Services","year":"2016","unstructured":"US Department of Health & Human Services. OPTN\/UNOS Registration Fee Increase First Time Since 2013. 2016 Available from: http:\/\/www.hhs.gov\/; [3 July 2018]."},{"key":"4974_CR34","unstructured":"AARP Public policy institute and National Alliance for caregiving, Caregiving in the US, N.a.A.P.P. Institute, Editor. 2015."},{"key":"4974_CR35","volume-title":"UNOS Bylaws","author":"United Network for Organ Sharing","year":"2015","unstructured":"United Network for Organ Sharing. UNOS Bylaws. 2015 Available from: https:\/\/www.unos.org\/wp-content\/uploads\/unos\/UNOS_Bylaws.pdf; [3 July 2018]; ."},{"key":"4974_CR36","volume-title":"Labor Force Statistics","author":"US Bureau of Labor Statistics","year":"2018","unstructured":"US Bureau of Labor Statistics. Labor Force Statistics. 2018 Available from: https:\/\/www.bls.gov\/data\/; [10 July 2018]."},{"key":"4974_CR37","volume-title":"Employment Ratio by Sex and Age Group","author":"Organisation for Economic Co-operation and Development","year":"2018","unstructured":"Organisation for Economic Co-operation and Development. Employment Ratio by Sex and Age Group 2018 Available from: https:\/\/stats.oecd.org\/index.aspx?queryid=54742; [8 July 2018]."},{"key":"4974_CR38","doi-asserted-by":"crossref","unstructured":"Witt, E. and M. DiBonaventura, Work productivity loss and activity impairment across nineteen medical conditions in a representative sample of us adults. , P. Poster Presented at the ISPOR 20th Annual International Meeting, PA, USA, Editor. 2015.","DOI":"10.1016\/j.jval.2015.03.1018"},{"issue":"6","key":"4974_CR39","doi-asserted-by":"publisher","first-page":"1861","DOI":"10.1681\/ASN.2015060648","volume":"27","author":"YH Hwang","year":"2016","unstructured":"Hwang YH, et al. Refining genotype-phenotype correlation in autosomal dominant polycystic kidney disease. J Am Soc Nephrol. 2016;27(6):1861\u20138.","journal-title":"J Am Soc Nephrol"},{"key":"4974_CR40","unstructured":"Munnell AH. The Average Retirement Age \u2013 An Update. Chestnut Hill: Center for Retirement Research at Boston College; 2015. Available from: http:\/\/crr.bc.edu\/wp-content\/uploads\/2015\/03\/IB_15-4_508_rev.pdf; [27 March 2017]."},{"key":"4974_CR41","volume-title":"United States Bureau of Labor Statistics","author":"US Bureau of Labor Statistics","year":"2017","unstructured":"US Bureau of Labor Statistics. United States Bureau of Labor Statistics. 2017c Available from: https:\/\/www.bls.gov\/home.htm; [17 January 2017]"},{"issue":"2","key":"4974_CR42","doi-asserted-by":"publisher","first-page":"155","DOI":"10.4088\/JCP.14m09298","volume":"76","author":"PE Greenberg","year":"2015","unstructured":"Greenberg PE, et al. The economic burden of adults with major depressive disorder in the United States (2005 and 2010). J Clin Psychiatry. 2015;76(2):155\u201362.","journal-title":"J Clin Psychiatry"},{"key":"4974_CR43","unstructured":"Albert, S., R. Schulz, and A. Colombi, The MetLife study of working caregivers and employer healthcare costs, I.o.A. University of Pittsburg, National Alliance for Caregiving, MetLife Mature Market Institute., Editor. 2010."},{"issue":"7","key":"4974_CR44","doi-asserted-by":"publisher","first-page":"2316","DOI":"10.1093\/ndt\/gfr007","volume":"26","author":"RS Suri","year":"2011","unstructured":"Suri RS, et al. Burden on caregivers as perceived by hemodialysis patients in the frequent hemodialysis network (FHN) trials. Nephrol Dial Transplant. 2011;26(7):2316\u201322.","journal-title":"Nephrol Dial Transplant"},{"key":"4974_CR45","unstructured":"Azzabi I, et al. Medicare claims analysis results on the medical costs associated with autosomal dominant polycystic kidney disease (ADPKD) in the US. Gaithersburg: Covance Market Access Services; 2011."},{"key":"4974_CR46","volume-title":"Uncompensated Care for Uninsured in 2013: A Detailed Examination. The Kaiser commission on Medicaid and the Unisured","author":"TA Coughlin","year":"2014","unstructured":"Coughlin, T.A., et al. Uncompensated Care for Uninsured in 2013: A Detailed Examination. The Kaiser commission on Medicaid and the Unisured 2014 Available from: http:\/\/kff.org\/uninsured\/report\/uncompensated-care-for-the-uninsured-in-2013-a-detailed-examination\/; [cited 27 March 2017]"},{"issue":"4","key":"4974_CR47","doi-asserted-by":"publisher","first-page":"805","DOI":"10.1053\/ajkd.2002.32001","volume":"39","author":"AG Belasco","year":"2002","unstructured":"Belasco AG, Sesso R. Burden and quality of life of caregivers for hemodialysis patients. Am J Kidney Dis. 2002;39(4):805\u201312.","journal-title":"Am J Kidney Dis"},{"issue":"10 Suppl","key":"4974_CR48","first-page":"S163","volume":"23","author":"L Golestaneh","year":"2017","unstructured":"Golestaneh L, et al. All-cause costs increase exponentially with increased chronic kidney disease stage. Am J Manag Care. 2017;23(10 Suppl):S163\u201372.","journal-title":"Am J Manag Care"},{"issue":"1","key":"4974_CR49","doi-asserted-by":"publisher","first-page":"368","DOI":"10.1186\/s12913-017-2303-3","volume":"17","author":"MN Ozieh","year":"2017","unstructured":"Ozieh MN, et al. Trends in healthcare expenditure in United States adults with chronic kidney disease: 2002-2011. BMC Health Serv Res. 2017;17(1):368.","journal-title":"BMC Health Serv Res"},{"issue":"6","key":"4974_CR50","first-page":"952","volume":"19","author":"SH Allaire","year":"1992","unstructured":"Allaire SH, et al. The economic impacts of juvenile rheumatoid arthritis. J Rheumatol. 1992;19(6):952\u20135.","journal-title":"J Rheumatol"},{"issue":"2","key":"4974_CR51","doi-asserted-by":"publisher","first-page":"73","DOI":"10.1016\/S0049-0172(97)80008-X","volume":"27","author":"L Wilson","year":"1997","unstructured":"Wilson L. Cost-of-illness of scleroderma: the case for rare diseases. Semin Arthritis Rheum. 1997;27(2):73\u201384.","journal-title":"Semin Arthritis Rheum"},{"issue":"6","key":"4974_CR52","doi-asserted-by":"publisher","first-page":"1052","DOI":"10.1681\/ASN.2009121291","volume":"21","author":"MC Hogan","year":"2010","unstructured":"Hogan MC, et al. Randomized clinical trial of long-acting somatostatin for autosomal dominant polycystic kidney and liver disease. J Am Soc Nephrol. 2010;21(6):1052\u201361.","journal-title":"J Am Soc Nephrol"},{"issue":"11","key":"4974_CR53","doi-asserted-by":"publisher","first-page":"1765","DOI":"10.2215\/CJN.03960318","volume":"13","author":"FT Chebib","year":"2018","unstructured":"Chebib FT, Torres VE. Recent advances in the Management of Autosomal Dominant Polycystic Kidney Disease. Clin J Am Soc Nephrol. 2018;13(11):1765\u201376.","journal-title":"Clin J Am Soc Nephrol"},{"issue":"9903","key":"4974_CR54","doi-asserted-by":"publisher","first-page":"1485","DOI":"10.1016\/S0140-6736(13)61407-5","volume":"382","author":"A Caroli","year":"2013","unstructured":"Caroli A, et al. Effect of longacting somatostatin analogue on kidney and cyst growth in autosomal dominant polycystic kidney disease (ALADIN): a randomised, placebo-controlled, multicentre trial. Lancet. 2013;382(9903):1485\u201395.","journal-title":"Lancet"},{"issue":"9","key":"4974_CR55","doi-asserted-by":"publisher","first-page":"830","DOI":"10.1056\/NEJMoa1003491","volume":"363","author":"G Walz","year":"2010","unstructured":"Walz G, et al. Everolimus in patients with autosomal dominant polycystic kidney disease. N Engl J Med. 2010;363(9):830\u201340.","journal-title":"N Engl J Med"},{"key":"4974_CR56","volume-title":"Drug Approval Package: Jynarque (tolvaptan)","author":"US Food & Drug Administration","year":"2018","unstructured":"US Food & Drug Administration. Drug Approval Package: Jynarque (tolvaptan). 2018 Available from: https:\/\/www.accessdata.fda.gov\/drugsatfda_docs\/nda\/2018\/204441Orig1s000TOC.cfm[26 February 2019]."},{"issue":"10","key":"4974_CR57","doi-asserted-by":"publisher","first-page":"2458","DOI":"10.1681\/ASN.2018060590","volume":"29","author":"FT Chebib","year":"2018","unstructured":"Chebib FT, et al. A practical guide for treatment of rapidly progressive ADPKD with Tolvaptan. J Am Soc Nephrol. 2018;29(10):2458\u201370.","journal-title":"J Am Soc Nephrol"}],"container-title":["BMC Health Services Research"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1186\/s12913-020-4974-4.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/article\/10.1186\/s12913-020-4974-4\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1186\/s12913-020-4974-4.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2021,2,20]],"date-time":"2021-02-20T02:51:13Z","timestamp":1613789473000},"score":1,"resource":{"primary":{"URL":"https:\/\/bmchealthservres.biomedcentral.com\/articles\/10.1186\/s12913-020-4974-4"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2020,2,18]]},"references-count":57,"journal-issue":{"issue":"1","published-print":{"date-parts":[[2020,12]]}},"alternative-id":["4974"],"URL":"https:\/\/doi.org\/10.1186\/s12913-020-4974-4","relation":{"has-review":[{"id-type":"doi","id":"10.3410\/f.737404060.793571693","asserted-by":"object"}]},"ISSN":["1472-6963"],"issn-type":[{"value":"1472-6963","type":"electronic"}],"subject":[],"published":{"date-parts":[[2020,2,18]]},"assertion":[{"value":"7 June 2019","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"11 February 2020","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"18 February 2020","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"This study did not use patient-level data and did not require ethics approval.","order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethics approval and consent to participate"}},{"value":"The study did not use individual patient data.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Consent for publication"}},{"value":"MC, AMM, AG, and MGL are employees of Analysis Group, Inc., that has received consultancy fees from Otsuka Pharmaceutical Development & Commercialization, Inc. MSA and DO are employees of Otsuka Pharmaceutical Development & Commercialization, Inc., and may own stocks\/stock options.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}],"article-number":"126"}}